SURUNKALI KASALLIKLARNI OLDINI OLISHDA ERTA SKRININGNING AHAMIYATI
Keywords:
Kalit so'zlar: erta skrining, surunkali kasalliklarni oldini olish, erta tashxis, xavf omillari, aholi xabardorligi, skrining dasturlari, profilaktiv tibbiyot, iqtisodiy samaradorlik, yurak-qon tomir kasalliklari, qandli diabet, saraton skriningi.Abstract
Ushbu maqolada surunkali kasalliklarni oldini olishda samarali vosita sifatida erta skriningning roli batafsil ko'rib chiqiladi. Yuqori xolesterin, gipertoniya, ortiqcha vazn va irsiy moyillik kabi xavf omillarini erta bosqichlarda aniqlashning ahamiyati, shuningdek ushbu omillarning yurak-qon tomir kasalliklari, qandli diabet, onkologik va o'pka patologiyalari rivojlanishiga ta'siri tahlil qilinadi.
Mualliflar erta tashxis kasallanish va o'limni sezilarli darajada kamaytirish, davolash samaradorligini oshirish hamda murakkab tibbiy aralashuvlar zaruriyatini minimallashtirishdagi ilmiy-amaliy ahamiyatiga alohida e'tibor qaratadi. Shuningdek, skrining choralarini sog'liqni saqlash tizimiga integratsiya qilish zarurligi ta'kidlanib, profilaktik skriningning afzalliklari to'g'risida aholi xabardorligini oshirishning muhimligi belgilab qo'yiladi.
Maqolada muvaffaqiyatli skrining dasturlarining misollari, ularning jamoat sog'lig'iga ta'siri va amalga oshirishning iqtisodiy manfaatlari tahlil qilinadi. Sog'liqni saqlash xizmatlarining yetarli darajada mavjud emasligi, aholi qamrovining pastligi va xabardorlikning etishmasligi bilan bog'liq to'siqlar muhokama qilinadi. Skrining dasturlarini takomillashtirish bo'yicha tavsiyalar berilgan bo'lib, ular zamonaviy texnologiyalarni joriy etish, shaxsiylashtirilgan yondashuvlar va tibbiyot xodimlari hamda aholi orasida ta'lim tashabbuslarini kengaytirishni o'z ichiga oladi.
References
1. World Health Organization. Noncommunicable diseases: progress monitor 2022. Geneva: WHO, 2022.
2. Yusuf S. et al. Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries // The Lancet. — 2020. — Vol. 395. — P. 795–808.
3. American Diabetes Association. Standards of Medical Care in Diabetes — 2023 // Diabetes Care. — 2023. — Vol. 46, Suppl. 1.
4. Grundy S.M. et al. 2018 AHA/ACC/AACVPR/AAPA guideline on the management of blood cholesterol // Circulation. — 2019. — Vol. 139. — P. e1082–e1143.
5. Whelton P.K. et al. 2017 ACC/AHA High Blood Pressure Clinical Practice Guideline // Hypertension. — 2018. — Vol. 71. — P. e13–e115.
6. Khoury M.J. et al. Population screening in the age of genomic medicine // New England Journal of Medicine. — 2003. — Vol. 348. — P. 50–58.
7. Oeffinger K.C. et al. Breast cancer screening for women at average risk // JAMA. — 2015. — Vol. 314. — P. 1599–1614.
8. Arbyn M. et al. Predictions on the burden of cervical cancer in Europe // Annals of Oncology. — 2007. — Vol. 18. — P. 1361–1369.
9. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin // NEJM. — 2002. — Vol. 346. — P. 393–403.
10. Brenner H. et al. Long-term risk of colorectal cancer after negative colonoscopy // New England Journal of Medicine. — 2011. — Vol. 365. — P. 1298–1306.
